DB:P731

Stock Analysis Report

Executive Summary

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada.

Snowflake

Fundamentals

Reasonable growth potential and fair value.

Share Price & News

How has Medexus Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.04%

DB:P731

0.8%

DE Pharmaceuticals

-0.7%

DE Market


1 Year Return

-32.3%

DB:P731

-11.0%

DE Pharmaceuticals

-10.8%

DE Market

P731 underperformed the Pharmaceuticals industry which returned -9.7% over the past year.

P731 underperformed the Market in Germany which returned -10% over the past year.


Share holder returns

P731IndustryMarket
7 Day-0.04%0.8%-0.7%
30 Day-9.8%6.4%-3.9%
90 Day-10.1%10.5%-4.3%
1 Year-32.3%-32.3%-8.0%-11.0%-8.0%-10.8%
3 Yearn/a-11.7%-19.3%9.8%0.3%
5 Yearn/a31.3%9.8%24.0%6.8%

Price Volatility Vs. Market

How volatile is Medexus Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Medexus Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Medexus Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).

Medexus Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Medexus Pharmaceuticals is loss making, we can't compare its value to the DE Pharmaceuticals industry average.

Medexus Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Medexus Pharmaceuticals, we can't assess if its growth is good value.


Price Based on Value of Assets

Medexus Pharmaceuticals is good value based on assets compared to the DE Pharmaceuticals industry average.


Next Steps

Future Growth

How is Medexus Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

53.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Medexus Pharmaceuticals's revenue is expected to grow by 18.9% yearly, however this is not considered high growth (20% yearly).

Medexus Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.

Medexus Pharmaceuticals's revenue growth is expected to exceed the Germany market average.

Medexus Pharmaceuticals's earnings growth is expected to exceed the Germany market average.

Medexus Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.


Earnings per Share Growth Estimates


Future Return on Equity

Medexus Pharmaceuticals is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Medexus Pharmaceuticals performed over the past 5 years?

-4.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Medexus Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Medexus Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Medexus Pharmaceuticals's 1-year growth to the DE Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Medexus Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Medexus Pharmaceuticals has efficiently used its assets last year compared to the DE Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Medexus Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Medexus Pharmaceuticals's financial position?


Financial Position Analysis

Medexus Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Medexus Pharmaceuticals's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Medexus Pharmaceuticals's level of debt (60.5%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (0.2% vs 60.5% today).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 2.1x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Medexus Pharmaceuticals has sufficient cash runway for more than 3 years based on current free cash flow.

Medexus Pharmaceuticals has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 44.9% each year.


Next Steps

Dividend

What is Medexus Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Medexus Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Medexus Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Medexus Pharmaceuticals has not reported any payouts.

Unable to verify if Medexus Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Medexus Pharmaceuticals has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Medexus Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

5.5yrs

Average management tenure


CEO

Ken d'Entremont 0

0.7yrs

Tenure

0

Mr. Kenneth d'Entremont also known as Ken, has been Chief Executive Officer at Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.) since December 2018 and has been its Chief Operating Officer since Oct ...


Management Age and Tenure

5.5yrs

Average Tenure

55yo

Average Age

The average tenure for the Medexus Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

0.8yrs

Average Tenure

56.5yo

Average Age

The average tenure for the Medexus Pharmaceuticals board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyCA$22,68316 Oct 18
Benoit Gravel
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares6,666.66
Max PriceCA$3.40
SellCA$11621 Sep 18
Knight Therapeutics Inc.
EntityCompany
Shares33.33
Max PriceCA$3.47
SellCA$17,05719 Sep 18
Knight Therapeutics Inc.
EntityCompany
Shares4,933.33
Max PriceCA$3.46
SellCA$172,66017 Sep 18
Knight Therapeutics Inc.
EntityCompany
Shares50,099.95
Max PriceCA$3.45
SellCA$12,16431 Aug 18
Knight Therapeutics Inc.
EntityCompany
Shares2,666.66
Max PriceCA$4.56

Ownership Breakdown


Management Team

  • Normand Chartrand (60yo)

    Consultant

    • Tenure: 0.8yrs
    • Compensation: CA$15.00k
  • Terri Shoemaker

    President of United States Operations

    • Tenure: 0.7yrs
  • Sylvain Chretien (55yo)

    President & Director

    • Tenure: 5.7yrs
    • Compensation: CA$367.19k
  • Benoît Hébert (51yo)

    Vice President of Business Development & Licensing

    • Tenure: 9.9yrs
    • Compensation: CA$306.66k
  • Roland Boivin

    Chief Financial Officer

    • Tenure: 6.1yrs
    • Compensation: CA$300.83k
  • Richard Labelle

    Vice President of Sales & Marketing

    • Tenure: 5.5yrs
    • Compensation: CA$285.55k
  • Ken d'Entremont

    CEO, COO & Director

    • Tenure: 0.7yrs

Board Members

  • Peter van der Velden (57yo)

    Chairman of the Board

    • Tenure: 0.7yrs
  • Michael Mueller (60yo)

    Independent Director

    • Tenure: 5.3yrs
    • Compensation: CA$15.00k
  • Benoit Gravel

    Independent Director

    • Tenure: 1.9yrs
    • Compensation: CA$7.50k
  • Adele Gulfo (56yo)

    Director

    • Tenure: 0.2yrs
  • Sylvain Chretien (55yo)

    President & Director

    • Tenure: 5.7yrs
    • Compensation: CA$367.19k
  • Stephen Nelson

    Director

    • Tenure: 0.8yrs
  • Ken d'Entremont

    CEO, COO & Director

    • Tenure: 0.7yrs

Company Information

Medexus Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Medexus Pharmaceuticals Inc.
  • Ticker: P731
  • Exchange: DB
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$58.252m
  • Listing Market Cap: CA$39.516m
  • Shares outstanding: 14.56m
  • Website: https://www.medexus.com

Number of Employees


Location

  • Medexus Pharmaceuticals Inc.
  • 1 Place du Commerce
  • Suite 225
  • Verdun
  • Quebec
  • H3E 1A2
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MDPTSXV (TSX Venture Exchange)YesCommon SharesCACADDec 2013
PDDP.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDDec 2013
P731DB (Deutsche Boerse AG)YesCommon SharesDEEURDec 2013

Biography

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company’s primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid art ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/20 22:15
End of Day Share Price2019/08/20 00:00
Earnings2019/03/31
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.